Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | TTR | P02766 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | APP | P05067 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | DPP4 | P27487 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2042662 | 1.00 | KDM4E (0.71) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| SCHEMBL5598948 | 0.85 | KDM4E (0.74) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| SCHEMBL2221673 | 0.85 | KDM4E (0.74) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL28797555 | 0.84 | KDM4E (0.67) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL9308251 | 0.84 | KDM4E (0.67) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL23358 | 0.83 | KDM4E (1.00) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL30501140 | 0.83 | KDM4E (1.00) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL7064846 | 0.83 | KDM4E (1.00) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL21114743 | 0.83 | KDM4E (1.00) | KDM4EMAPTTTRKMT2AHSD17B10 | |
| Caffeic Acid SCHEMBL3682144 | 0.83 | KDM4E (1.00) | KDM4EMAPTTTRKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007518673-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-20060270733-A1 | 2-Aminobenzoyl derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2006-11-30 | — | — | US | claimed |
| EP-1644316-A4 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2006-10-25 | — | — | EP | claimed |
| EP-1644316-A2 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2006-04-12 | — | — | EP | claimed |
| WO-2004112690-A2 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-12-29 | — | — | WO | claimed |
| US-8309767-B2 | 2-aminobenzoyl derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2012-11-13 | — | — | US | disclosed |
| US-7355054-B2 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2008-04-08 | — | — | US | disclosed |
| US-20060270733-A1 | 2-Aminobenzoyl derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2006-11-30 | — | — | US | disclosed |
| EP-1644316-A4 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2006-10-25 | — | — | EP | disclosed |
| EP-1644316-A2 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2006-04-12 | — | — | EP | disclosed |
| US-20050159463-A1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-07-21 | — | — | US | disclosed |
| EP-1189583-B1 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2005-07-20 | — | — | EP | disclosed |
| US-6858642-B1 | Indole derivatives | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-02-22 | — | — | US | disclosed |
| WO-2004112690-A2 | 2-AMINOBENZOYL DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-12-29 | — | — | WO | disclosed |
| EP-1189583-A4 | INDOLE DERIVATIVES | NEURIM PHARMA 1991 (IL) | 2004-04-14 | — | — | EP | disclosed |
| EP-1189583-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000072815-A1 | INDOLE DERIVATIVES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270733-A1 | 2-Aminobenzoyl derivatives | AADAC, ABAT, GLS | KDM4E 1568/4885MAPT 2634/4885TTR 1151/4885 |
| US-20050159463-A1 | Indole derivatives | IDO1, IDO2, H1-0 | KDM4E 303/4885MAPT 3887/4885TTR 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.